- Home
- CYTK
as 10-04-2024 4:00pm EST
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 6.7B | IPO Year: | 2004 |
| Target Price: | $81.79 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.83 - $110.25 | Next Earning Date: | 10-31-2024 |
| Revenue: | $3,134,000 | Revenue Growth: | -68.51% |
| Revenue Growth (this year): | -0.61% | Revenue Growth (next year): | 827.22% |
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | CYTK | EVP Research & Development | Oct 1 '24 | Sell | $52.10 | 7,300 | $380,297.00 | 118,920 | |
| Blum Robert I | CYTK | President & CEO | Sep 30 '24 | Sell | $52.14 | 5,000 | $260,700.00 | 397,456 | |
| PARSHALL B LYNNE | CYTK | Director | Sep 9 '24 | Sell | $54.92 | 5,000 | $274,600.00 | 20,600 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Sep 3 '24 | Sell | $57.01 | 7,384 | $420,973.16 | 118,920 | |
| Blum Robert I | CYTK | President & CEO | Sep 3 '24 | Sell | $57.03 | 5,000 | $285,150.00 | 397,456 | |
| PARSHALL B LYNNE | CYTK | Director | Aug 26 '24 | Sell | $57.26 | 5,000 | $286,300.00 | 20,600 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Aug 20 '24 | Sell | $56.25 | 7,300 | $410,638.00 | 118,920 | |
| Blum Robert I | CYTK | President & CEO | Aug 12 '24 | Sell | $55.17 | 11,500 | $634,455.00 | 397,456 | |
| PARSHALL B LYNNE | CYTK | Director | Aug 12 '24 | Sell | $55.20 | 5,000 | $276,000.00 | 20,600 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Aug 6 '24 | Sell | $53.72 | 7,300 | $392,090.00 | 118,920 |
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4 days ago
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
Insider Monkey
6 days ago
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
GlobeNewswire
6 days ago
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
MT Newswires
9 days ago
Cytokinetics New Analysis of Heart Medication Study Shows Beneficial Changes
GlobeNewswire
9 days ago
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
GlobeNewswire
12 days ago
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Investor's Business Daily
17 days ago
How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease
Compare CYTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.